Rankings
▼
Calendar
TSHA Q1 2023 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena
TSHA
Taysha Gene Therapies, Inc.
$1B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
Gross Profit
$4M
86.6% margin
Operating Income
-$17M
-351.9% margin
Net Income
-$18M
-374.5% margin
EPS (Diluted)
$-0.28
QoQ Revenue Growth
+88.1%
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$24M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$102M
Total Liabilities
$117M
Stockholders' Equity
-$15M
Cash & Equivalents
$63M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$0
—
Gross Profit
$4M
$0
—
Operating Income
-$17M
-$50M
+66.6%
Net Income
-$18M
-$50M
+65.0%
← FY 2023
All Quarters
Q2 2023 →